PAR 6.52% 24.5¢ paradigm biopharmaceuticals limited..

ConclusionsThis study shows for the first time the effects of...

  1. 54 Posts.
    lightbulb Created with Sketch. 15

    Conclusions

    This study shows for the first time the effects of PPS on human primary osteocytes isolated from the subchondral bone in patients with osteoarthritis of the knee. It is also the first demonstration of the production and secretion of NGF/proNGF by this cell type. PPS inhibited basal and TNFα-induced levels of proNGF secretion and TNFα induced NGF mRNA expression. PPS also inhibited TNFα-induced levels of the collagenase MMP-13. Together, this provides evidence that PPS may act at multiple levels to suppress the release of NGF and potentially other pain mediators in the subchondral bone, to ameliorate pain associated with knee osteoarthritis.

    Last edited by 3gig4me: 27/09/19
 
watchlist Created with Sketch. Add PAR (ASX) to my watchlist
(20min delay)
Last
24.5¢
Change
0.015(6.52%)
Mkt cap ! $85.7M
Open High Low Value Volume
23.0¢ 24.5¢ 23.0¢ $116.0K 491.1K

Buyers (Bids)

No. Vol. Price($)
1 50000 23.5¢
 

Sellers (Offers)

Price($) Vol. No.
24.5¢ 33682 3
View Market Depth
Last trade - 16.10pm 21/06/2024 (20 minute delay) ?
PAR (ASX) Chart
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.